Sorrento Therape
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, includi… Read more
Sorrento Therape (SRNE) - Total Liabilities
Latest total liabilities as of June 2023: $654.65 Million USD
Based on the latest financial reports, Sorrento Therape (SRNE) has total liabilities worth $654.65 Million USD as of June 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sorrento Therape - Total Liabilities Trend (2003–2022)
This chart illustrates how Sorrento Therape's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sorrento Therape Competitors by Total Liabilities
The table below lists competitors of Sorrento Therape ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ARKEMA (V1S.SG)
STU:V1S
|
Germany | €7.20 Billion |
|
Fabled Copper Corp
PINK:FBCPF
|
USA | $762.02K |
|
ARROWHEAD RESEARCH
BE:HDP1
|
Germany | €544.78 Million |
|
LAS VEGAS SANDS
BE:LCR
|
Germany | €17.71 Billion |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
USA | $84.60 Million |
|
Alaska Power & Telephone Company
PINK:APTL
|
USA | $125.03 Million |
Liability Composition Analysis (2003–2022)
This chart breaks down Sorrento Therape's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sorrento Therape's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sorrento Therape (2003–2022)
The table below shows the annual total liabilities of Sorrento Therape from 2003 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $494.51 Million | -19.81% |
| 2021-12-31 | $616.69 Million | +56.09% |
| 2020-12-31 | $395.09 Million | -24.73% |
| 2019-12-31 | $524.88 Million | +25.99% |
| 2018-12-31 | $416.59 Million | +85.15% |
| 2017-12-31 | $225.00 Million | -28.59% |
| 2016-12-31 | $315.08 Million | +55.53% |
| 2015-12-31 | $202.58 Million | +517.10% |
| 2014-12-31 | $32.83 Million | +27.37% |
| 2013-12-31 | $25.77 Million | +4311.86% |
| 2012-12-31 | $584.17K | +62.57% |
| 2011-12-31 | $359.34K | -40.50% |
| 2010-12-31 | $603.96K | +71.06% |
| 2009-12-31 | $353.07K | +15040.22% |
| 2008-12-31 | $2.33K | -29.01% |
| 2007-12-31 | $3.29K | -99.03% |
| 2006-12-31 | $339.77K | +945.44% |
| 2005-12-31 | $32.50K | -90.46% |
| 2004-12-31 | $340.53K | +0.22% |
| 2003-12-31 | $339.77K | -- |